97055 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Receptors; Cell surface antigens; Cell surface determinants Molecules with a "CD"-designation not provided for elsewhere
Inducible fluorescently-tagged protein expression system
#1202Mannose immunogens for HIV-1
#1203METHODS AND COMPOSITIONS FOR THE TREATMENT OF FIBROTIC CONDITIONS AND IMPAIRED LUNG FUNCTION AND TO ENHANCE LYMPHOCYTE PRODUCTION
#1204Crystal structure of the N-terminal domain of angiotensin converting enzyme and uses thereof
#1205Crystal structure of an angiotensin-converting enzyme (ACE) and uses thereof
#1206Permissive cells and uses thereof
#1207Macrophage cell-lines for propagation of porcine reproductive and respiratory syndrome virus
#1208Porcine CTLA-4 for xenograft-specific immunosuppression
#1209CANINE CD20 GENE
#1210CD133 epitopes
#1211NUCLEIC ACID ENCODING RECEPTOR TYPE PROTEIN KINASE
#1212Composition and method for facilitating the internalization of a therapeutic agent into a cell
#1213Compositions and methods for treating diseases associated with angiogenesis and inflammation
#1214Methods for producing soluble membrane-spanning proteins
#1215Monoclonal antibodies
#1216Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof
#1217Human CD59 mutants with modulated complement binding activity
#1218Nucleic acid molecules encoding GPR84
#1219CHIMERIC NON-HUMAN ANIMAL
#1220Mass spectrometric methods and products
#1221Method for producing antibodies
#1222Soluble heterodimeric CD94/NKG2 receptors fusion proteins
#1223COMPOSITIONS AND METHODS FOR INHIBITING SHIGA TOXIN AND SHIGA-LIKE TOXIN
#1224Penumbra Nucleic Acid Molecules, Proteins and Uses Thereof
#1225Methods and animal model for analyzing age-related macular degeneration
#1226Methods for producing soluble membrane spanning proteins
#1227Immunogenic peptides
#1228Soluble CD14 antigen
#1229Soluble Endoglin Compounds for the Treatment and Prevention of Cancer
#1230Antiviral compositions comprising a multiple branched peptide construct containing human CD38 leukocyte surface antigen polypeptides
#1231COAGULATION FACTOR III POLYMORPHISMS ASSOCIATED WITH PREDICTION OF SUBJECT OUTCOME AND RESPONSE TO THERAPY
#1232Antibodies against CD38 for treatment of multiple myeloma
#1233Crystal structure of an angiotensin-converting enzyme (ACE) and uses thereof
#1234Preventive/Remedy for Cancer
#1235Pancreatic cancer targets and uses thereof
#1236Methods of reducing a viral infection and kits therefore
#1237Microbicidal compositions comprising human CD38 polypeptides derived from the extracellular membrane-proximal region
#1238CD33-Like Protein
#1239Immunogenic CD19 peptides
#1240Methods of Therapy and Diagnosis Using Immunotargeting of CD84Hy1-expressing Cells
#1241Tyrosylprotein sulfotransferases and methods of use thereof
#1242Methods and Materials Relating to CD84-like Polypeptides and Polynucleotides
#1243METHODS AND COMPOSITIONS FOR THE TREATMENT OF FIBROTIC CONDITIONS & IMPAIRED LUNG FUNCTION & TO ENHANCE LYMPHOCYTE PRODUCTION
#1244Assay kit and antibody for human low molecular weight CD14
#1245Hepatitis C receptor protein CD81
#1246Methods and compositions concerning antibodies that bind CD84-like polypeptides
#1247Attractin/mahogany-like polypeptides
#1248Canine Cd20 Gene
#1249Chimeric proteins with phosphatidylserine binding domains
#1250Complement receptor 2 targeted complement modulators
#1251MODULATION OF CD200 RECEPTORS
#1252Ligands and libraries of ligands
#1253Methods and Materials Relating to CD84-like Polypeptides and Polynucleotides
#1254CD163-binding conjugates
#1255Methods of diagnosing acute myeloid leukemia using nucleic acids encoding FLT3 kinase
#1256Compounds that Block the C5a Receptor and Their Use in Therapy
#1257Targeting complement factor H for treatment of diseases
#1258Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
#1259Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof
#1260Hybrid and chimeric polypeptides that regulate activation of complement
#1261ELICITING IMPROVED IMMUNE RESPONSES
#1262COMPOSITIONS AND METHODS FOR TREATMENT
#1263Compositions and methods for treating diseases associated with angiogenesis and inflammation
#1264CD47 related compositions and methods for treating immunological diseases and disorders
#1265GD3-mimetic peptides
#1266Modified truncated complement system regulators
#1267Neutralizing antibodies and methods of use thereof
#1268T cell inhibitory receptor compositions and uses thereof
#1269Compositions and methods for inhibiting microbial adhesion
#1270Human cytotoxic T-lymphoctye epitope and its agonist eptiope from the non-variable number of tandem repeat sequence of MUC-1
#1271Canine CD20 Compositions
#1272Fluid flow meter body with high immunity to inlet/outlet flow disturbances
#1273Isolation, selection and propagation of animal transgenic stem cells
#1274Antimicrobial carbohydrates and methods of using same
#1275Production of tissue factor in plants
#1276Transgenic mouse comprising a polynucleotide encoding human or humanized C5aR and methods of production and use
#1277Blood group antigens of different types for diagnostic and therapeutic applications
#1278Three-dimensional structure of complement receptor type 2 and uses thereof
#1279Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof
#1280Drug for preventing or treating heart diseases comprising CD9 gene
#1281Methods and materials relating to novel polypeptides and polynucleotides
#1282Cells for detection of enteroviruses
#1283Methods and compositions for inhibition of immune responses
#1284Methods for detecting human low molecular weight CD14
#1285Crystals of DPP-IV
#1286Hepatitis C receptor protein CD81
#1287CD147 binding molecules as therapeutics
#1288Dendritic Enriched Secreted Lymphocyte Activation Molecule
#1289COMPOUNDS TARGETED TO CELLULAR LOCATIONS
#1290Monoclonal antibody specific for CD43 epitope
#1291Crystals of DPP-IV
#1292B Cell Activation and Polypeptides Having CD14 Activity
#1293Antibodies to dendritc cells and human dendritic cell populations and uses thereof
#1294Heat shock protein binding fragments of CD91, and uses thereof
#1295Polypeptides, polynucleotides encoding same, antibodies thereagainst and methods of using same for diagnosing and treating cancer and skeletal disorders
#1296Technique for extending biological sugar chain via introduction of glycosyltransferase gene
#1297CD9/CD81 double-deficient non-human animal
#1298C3b/C4b complement receptor-like molecules and uses thereof
#1299Cell surface receptor isoforms and methods of identifying and using the same
#1300Methods and compositions for screening using diphtheria toxin constructs
#1301Animals with reduced body fat and increased bone density
#1302Chimeric proteins with phosphatidylserine binding domains
#1303Mannose immunogens for HIV-1
#1304Cleavable reagents for specific delivery to disease sites
#1305Transgenic mice expressing human CD20 and/or CD16
#1306Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
#1307Transgenic mice expressing human cd20
#1308Methods and vectors for improving nucleic acid expression
#1309Crystal structure of an angiotensin-converting enzyme (ACE) and uses thereof
#1310Methods for producing soluble membrane-spanning proteins
#1311Nucleic acid molecules for optimized CAB-2 expression and their use
#1312Cd47 partal peptdie and anti-shps-1 monoclonal antibody
#1313Identification of novel MS4A gene family members expressed by hematopoietic cells
#1314Animal model systems for viral pathogenesis of neurodegeneration, autoimmune demyelination, and diabetes
#1315Method for culturing cells in order to produce substances
#1316Tyrosylprotein sulfotransferases and methods of use thereof
#1317Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells
#1318CD147 binding molecules as therapeutics
#1319Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
#1320Soluble CD14 antigen
#1321Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
#1322GD3-mimetic peptides
#1323Use of soluble CD26 as inhibitor of angiogenesis and inflammation
#1324C3b/C4b complement receptor-like molecules and uses thereof
#1325Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
#1326Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof
#1327Novel human membrane proteins and polynucleotides encoding the same
#1328Isolated recombinant bovine soluble CD14 polypeptide, rbosCD14
#1329Three-dimensional structure of complement receptor type 2 and uses thereof
#1330Antigenic gp 100 compounds for therapy and diagnosis and methods of using same
#1331Tyrosylprotein sulfotransferases and methods of use thereof
#1332CD39/ecto-adpase for treatment of thrombotic and ischemic disorders
#1333Synthetic glycosulfopeptides and methods of synthesis thereof
#1334Angiotensin-converting enzyme-2 as a receptor for the SARS coronavirus
#1335CD7 as biomarker and therapeutic target for psoriasis
#1336Cellular permissivity factor for viruses and uses thereof
#1337Canine CD20 compositions
#1338Neutralizing antibodies and methods of use thereof
#1339Tissue targeted complement modulators
#1340Three-dimensional structure of dipeptidyl peptidase IV
#1341Diagnostic methods and gene therapy using reagents derived from the human metastasis suppressor gene KAI1
#1342Methods of blocking tissue destruction by autoreactive T cells
#1343Methods and vectors for generating antibodies in avian species and uses therefor
#1344Methods of blocking tissue destruction by autoreactive T cells
#1345Methods of blocking tissue destruction by autoreactive T cells
#1346Methods of blocking tissue destruction by autoreactive T cells
#1347CD38 splice variants and uses thereof
#1348Method of treating multiple sclerosis and related t-cell initiated tissue destruction by administering HSA/CD24
#1349Isolation, selection and propagation of animal transgenic stem cells
#1350Modulation of platelet adhesion based on the surface-exposed beta-switch loop of platelet glycoprotein IB-alpha
#1351Methods for protein production
#1352Chimeric nonhuman animal
#1353Populations of cells that express flk-2 receptors
#1354Identification of compounds that bind biliary glycoprotein and affect cytotoxic T lymphocyte activity
#1355Novel functions for decay accelerating factor (DAF) in inflammation
#1356Methods of modulating CD200
#1357Methods for purifying viral particles for gene therapy
#1358Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX
#1359Selectin ligand interactor cytoplasmic (SLIC-1), a P-selectin glycoprotein ligand (PSGL-1) binding protein
#1360Novel human membrane proteins and polynucleotides encoding the same
#1361C5a receptor
#1362CD200 receptors
#1363Nucleic acid encoding receptor type protein kinase
#1364Tumour associated antigen 791Tgp72
#1365Polymeric compounds
#1366Diagnosis and treatment of blood disorders
#1367Function of a haptoglobin-haemoglobin receptor and the uses thereof
#1368MHC class II antigen-presenting systems and methods for activating CD4T cells
#1369Antigenic gp100 (154-162) compounds for therapy and diagnosis and methods for using same
#1370Targeted particles and methods of using the same
#1371MHC class II antigen-presenting systems and methods for activating CD4T cells
#1372Immunogenic peptides
#1373Transgenic mice expressing heterologous complement receptor type 1 (CR1) molecules on erythrocytes and uses therefor
#1374Methods and materials relating to CD84-like polypeptides and polynucleotides
#1375Novel human membrane-associated protein and cell surface protein family members
#1376Polynucleotides encoding dendritic enriched secreted lymphocyte activation molecule
#1377Populations of cells that express FLK-1 receptors
#1378Composition for regulating production of proteins
#1379Fusion protein and nucleic acid encoding sequence thereof, and uses of the same
#1380Process for the purification of soluble PSGL-1 protein variants
#1381Variants of IgG-Fc fusion that provide for site-specific conjugation at the N-terminus